Skip to content

Brain Diseases on 7.0T Magnetic Resonance Imaging

Brain Diseases on 7.0T Magnetic Resonance Imaging

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05287750
Enrollment
200
Registered
2022-03-18
Start date
2022-01-01
Completion date
2026-09-01
Last updated
2022-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Tumor, Cerebrovascular Disease, MRI

Keywords

Brain tumor, Cerebrovascular disease, MRI, Ultra high field

Brief summary

This clinical trial studies the use of 7-Tesla (7T)and 3T magnetic resonance imaging (MRI) in detecting brain diseases. 7T MRI has increased detection sensitivity, including more accurate lesion delineation, higher inter-rater agreement. Diagnostic procedures such as 7T MRI may help ultimately improved diagnostic and therapies confidence to inform decision making than standard 3T MRI.

Detailed description

7T MRI increased detection sensitivity, attain superior anatomic resolution, higher spatial and spectral specificity of advanced quantitative techniques, and shorter scan times than 3T MRI. When applied clinically, these benefits translate to increased detection sensitivity, and ultimately improved diagnostic and therapies confidence to inform decision making. This study aim to detect the image characteristics and diagnostic accuracy of brain diseases on 7T MRI.

Interventions

DIAGNOSTIC_TESTMagnetic resonance imaging

Patients recruited will receive Magnetic resonance imaging.

Sponsors

Chinese PLA General Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Age≥18 and ≤80 * Having brain diseases (eg: brain tumor, cerebrovascular diseases) * Having no contraindications against MRI or intravenous contrast agent administration * Clinically stable

Exclusion criteria

* Age\<18 or \>80 * Pregnancy and other contraindication to MRI scan * Informed consent not obtained

Design outcomes

Primary

MeasureTime frameDescription
the correspondence between brain tumor cells found in the biopsies and region of interest(ROI) signal intension on the 7T MRI scan and 3T MRI scanwithin a month after biopsyPathological assessment of biopsy material compared with the lesion's contrast-enhancement signal intension to normal brain white mater on 7T MRI and 3T MRI
The visibility of white matter tracts on 7T MRIwithin a month after biopsyVisualization of white matter tracts will be done with the use of diffusion tensor imaging (DTI) on 7T MRI and measuring the mean diffusivity (MD) value on Post-processing workstation ,and analysis the correlation between these values and pathological.

Secondary

MeasureTime frameDescription
The correlation between the ROI's signal intension on 7T MRI scan and the KPS in 1 month after operationwithin a month after biopsyThe correlation analysis between the T1 contrast-enchanced signal intension, Regional cerebral blood flow on 7T MRI (clinical sequence and perfusion) scan and the KPS in 1 month after operation
The visibility of white matter tracts on 7T MRI and 3T MRISix months after the biopsyVisualization of white matter tracts will be done with the use of diffusion tensor imaging (DTI) on 7T MRI and 3T MRI. and analysis the difference of the mean diffusivity (MD) value between 7.0T MRI and 3.0T MRI

Countries

China

Contacts

Primary ContactKun Cheng, M.S.
dr_chengkun@163.com+86 19921784434

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026